Literature DB >> 265735

Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients.

Y C Cheng, B Domin, L S Lee.   

Abstract

A procedure for purifying human cytoplasmic and mitochondrial deoxycytidine kinase (NTP:deoxycytidine 5'-phosphotransferase, EC 2.7.1.74) was developed. Both purified isozymes have a similar molecular weight, activation energy and catalyze the reaction by a sequential mechanism. These two isozymes differ with respect to their substrate specificities. With cytoplasmic deoxycytidine kinase, ATP, GTP and TTP have the highest reaction velocity. Pyrimidine nucleoside triphosphates have higher affinity but lower V than purine nucleoside triphosphates. Cytidine and arabinosylcytidine can serve as substrates. With mitochondrial isozyme only ATP gives the highest reaction velocity. ATP and dATP have the same Km but different V values. Besides deoxycytidine, also deoxythymidine but not cytidine or arabinosylcytidine can serve as substrates. There are also differences between these two isozymes with respect to their sensitivity to inhibition. For cytoplasmic enzyme, Br5dCyd and Iodo5dCyd are not inhibitory. Both dCTP and UTP are competitive inhibitors (Ki 0.25 and 0.5 micronM, respectively) with respect to ATP. For mitochondrial isozyme both Br5dCyd and Iodo5dCyd are inhibitory and dCTP and TTP are competitive inhibitors (Ki 2 and 10 micronM, respectively) with respect to ATP.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 265735     DOI: 10.1016/0005-2744(77)90281-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Inhibition of replication of hepatitis B virus by cytallene in vitro.

Authors:  Y L Zhu; S B Pai; S H Liu; K L Grove; B C Jones; C Simons; J Zemlicka; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.

Authors:  L P Colly; D J Richel; M W Arentsen-Honders; M G Kester; P M ter Riet; R Willemze
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

3.  Direct photoaffinity-labelling of human deoxycytidine kinase with the feedback inhibitor dCTP.

Authors:  O Jansson; S Eriksson
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

4.  Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase.

Authors:  S H Liu; K L Grove; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus.

Authors:  K K Biron; S C Stanat; J B Sorrell; J A Fyfe; P M Keller; C U Lambe; D J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

6.  Use of the circuit simulation program SPICE2 for analysis of the metabolism of anticancer drugs.

Authors:  J C White
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

7.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells.

Authors:  J C White; J P Rathmell; R L Capizzi
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

9.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

Authors:  W Y Gao; T Shirasaka; D G Johns; S Broder; H Mitsuya
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.

Authors:  A Kemena; V Gandhi; D S Shewach; M Keating; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.